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Decapping protein 1a (Dcp1a) is found in P-bodies and functions in mRNA cap removal prior to its
degradation. The function and binding partners of Dcp1a have been thoroughly studied, however its
expression pattern is still unclear. In this study we have monitored Dcp1a expression along brain
development, neuronal differentiation and during cellular stress. We found that Dcp1a is hyper-
phosphorylated under these physiological conditions. We followed our observations and identiﬁed
the speciﬁc amino acid residues that are phosphorylated. These ﬁndings suggest a novel post-trans-
lational modiﬁcation that may inﬂuence the function of Dcp1a in response to various physiological
cues.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Regulation of mRNA degradation is a key step in the control of
gene expression [1]. In budding yeast, Saccharomyces cerevisiae
mRNAs are degraded via two pathways. In both pathways, removal
of the poly(A) tail by deadenylation is the initial step. After dead-
enylation, removal of the 50-cap structure by decapping enzymes
occurs and proceeds via 50–30 digestion of the transcript by the
exonuclease XrnI. Alternatively, mRNAs can be degraded from 30
to 50 by the exosome, a complex of several nucleases [2]. Messen-
ger RNA molecules that harbor premature-termination codons, are
subjected to rapid degradation via the non-sense mediated decay
(NMD) pathway. In this pathway mRNAs can go through acceler-
ated deadenylation followed by 30–50 exonucleolytic activity or
deadenylation-independent decapping, followed by 50–30 cleavage
[3,4].
Decapping is thus a key step in the 50–30 decay pathway because
it initiates the degradation of both normal and aberrant mRNAs [5].chemical Societies. Published by E
ransforming growth factor b;
cting transcription factor
(J. Blumenthal).In this process the 50-cap is cleaved by speciﬁc enzymes to release
a 7-methyl GDP product. Studies in S. cerevisiae identiﬁed two
interacting proteins, decapping protein 1p (Dcp1p) and Dcp2p
which are involved in mRNA decapping [6–8]. Dcp1p was also sug-
gested to be a phosphoprotein, however the locations and role of
its phosphorylation was not determined [7]. In humans, Dcp1p
and Dcp2p homologs, termed hDcp1a, hDcp1b, and hDcp2 were
identiﬁed. hDcp1a and hDcp2 interact with each other in an RNA
independent manner, and copurify with decapping activity
in vitro [9]. Another study suggested that Dcp1a also termed as
SMAD4-interacting transcription factor (SMIF), interacts with
SMAD4 protein and acts as a transcription co-activator in the
transforming growth factor b (TGF-b) pathway. Upon TGF-b activa-
tion, SMIF–SMAD4 complexes are found in the nucleus, and initi-
ates the expression of TGF-b/bone morphogenic protein (BMP)
regulated genes [10].
In this study we investigated the expression of Dcp1a using
ﬂuorescence microscopy and SDS–PAGE analysis. We found that
Dcp1a migrates as two distinct bands in different cell types and
that the upper band is a phosphorylated form of the protein. In
addition, arsenate treatment of 293 HEK cells, induced hyper-
phosphorylation of Dcp1a. When speciﬁc mutations were intro-
duced in the protein sequence, the phosphorylation of Dcp1a was
signiﬁcantly reduced. Our results suggest a possible link betweenlsevier B.V. All rights reserved.
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regulation.Fig. 1. Dcp1a expression and phosphorylation levels along brain development and
neuronal differentiation of P19 neurons. (A) protein samples of brain homogenates
from mice at different age, were seperated in 8% SDS–PAGE gell and examined for
the presence of Dcp1a protein (E15 – 15th embryonic day, NB – newborn,1W – 1
week, 7W – 7 weeks, 9M – 9 months). Phosphatase treatment of E15 homogenate,
prior to Western-blot analysis using Dcp1a antibody. (B) Protein samples of lysates
from non-differentiated (ND) and differentiated P19 neurons (D2–D8, day 2–8 post
RA application), were examined by using Dcp1a antibody, and actin antibody as
control.2. Materials and methods
2.1. Plasmids and antibodies
Polyclonal antibody against Dcp1a was a generous gift from
Jens Lykke-Andersen and Bertrand Seraphin [11]. YFP-Dcp1a con-
struct and TIAR antibodies were a gift from Nancy Kedersha [12].
2.2. Tissue culture, drug treatments and transfections
P19 cells were grown in minimal essential medium (MEM, Bio-
logical Industries Beit-Haemek, Israel), supplemented with 5%
heat-inactivated fetal calf serum in a humidiﬁed 5% CO2 incubator
at 37 C. P19ND (non-differentiated) Cells at day 0 (D0) were in-
duced to differentiate in the following manner: 1  106 cells were
seeded into a 90 mm petri dish in 10 ml of MEM-5%-FCS medium
and incubated with 1 mM all-trans retinoic acid (RA) (Sigma–Al-
drich, Rehovot, Israel) for 2 days in a humidiﬁed incubator. Cell
aggregates were than pelleted gently and fresh medium and RA
was added. After two more days of aggregation (D4), cells were
pelleted gently and pellet washed once with PBS. Pellet was then
incubated with trypsin (Biological Industries) for 1 min. and
mechanically disrupted with 2 ml of DMEM-2.5%-FCS into single
cell suspension. Cells were plated on poly-L-lysine covered tissue
culture plates and incubated for 24 h. Cytosine arabinoside (Sig-
ma–Aldrich) was added (D5) to a ﬁnal concentration of 5 mM
and cells left in the incubator for three more days, when a deﬁnite
neuronal phenotype was observed (D8).
HEK-293 cells were grown in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM; GIBCO BRL Company; Grand Island, USA), supple-
mented with 10% (v/v) fetal calf serum Biological Industries),
2 mM glutamine, 50 units/ml penicillin, and 50 lg/ml streptomy-
cin. In order to induce cellular stress response, cells were treated
with 1 mM sodium arsenate for 30 min (Sigma–Aldrich). 293
HEK cells were transfected using the calcium phosphate precipita-
tion method as described previously [13].
2.3. Brain homogenization and immunoblotting
C57/Black mice were anesthetized (ketamine) and decapitated.
Brains were dissected and then homogenized in 10-times volume
of buffer H (20 mM HEPES pH 7.4, 0.3 M sucrose, 1 mM EDTA sup-
plemented with 10 lg/ml aprotinin, 10 lg/ml leupeptin, 1 lg/ml
pepstatin, 1 mM phenylmethylsulfonylﬂuoride) by 15 strokes in
glass–teﬂon homogenizer. Protein levels were determined using
Bradford reagent. Equal amounts of protein were loaded on 10%
SDS–PAGE and transferred to nitrocellulose membranes. The
membranes were blocked in nonfat milk for 2 h, incubated with
primary antibodies, as indicated over night at 4 C, washed and
incubated with horseradish peroxidase-conjugated secondary
antibody for 1 h. Membranes were then developed with enhanced
chemiluminescence.
2.4. Immunostaining of ﬁxed cells
Cells were grown on coated coverslips with poly-L-lysine. Cells
were ﬁxed with 4% paraformaldehyde in 4% sucrose for 20 min at
room temperature as previously described [14]. Following perme-
abilization with 0.3% Triton X-100 for 3 min, and blocking with
blocking buffer (10% goat serum, 2% bovine serum albumin
(BSA), 1% glycine, and 0.1% Triton (Sigma–Aldrich) in phosphate-
buffered saline (PBS)), the slides were incubated with primaryantibodies as indicated for 1.5 h at room temperature, washed
and reacted with a secondary antibody conjugated to ﬂuorescein
isothiocyanate (FITC) or Cy3 as necessary. The slides were visual-
ized by confocal laser microscopy using 488 nm and 545 nm laser
excitations, for FITC and Cy3, respectively.
2.5. Site-directed mutagenesis
The mutations S315A, S319A and S321A were introduced into a
YFP-Dcp1a construct using the QuikChange Site-Directed
Mutagenesis Kit by Stratagene as speciﬁed by the manufacturer.
The following primers were used (from the 50 to 30 end): CCTACA-
CAATCCCGTTGGCCCCTGTTCTCAGTCC and GGACTGAGAACAGG-
GGCCAACGGGATTGTGTAGG for S315A; CGTTGAGCCCTGTTCTC-
GCTCCCACTCTGCCAGC and GCTGGCAGAGTGGGAGCGAGAACA-
GGGCTCAACG for S319A; GCCCTGTTCTCAGTCCCGCTCTGCCAGCT-
GAAGC and GCTTCAGCTGGCAGAGCGGGACTGAGAACAGGGC for
S321A; CCTACACAATCCCGTTGGCCCCTGTTCTCGCTCCCGCTCTGC-
CAGC and GCTGGCAGAGCGGGAGCGAGAACAGGGGCCAACGGG-
ATTGTGTAGG for S315A/S319A/S321A.
3. Results
3.1. Dcp1a is phosphorylated along neuronal development
We followed Dcp1a expression in brain homogenates frommice
at different ages. We found that Dcp1a migrates as two bands and
that the relative intensity of the bands changes during mouse
development (Fig. 1A). This pattern of expression is common in
proteins that undergo post-translational modiﬁcations, such as
phosphorylation. Therefore, we treated a protein sample taken
from E15 mouse brain with phosphatase prior to the Western-blot
analysis. The treated Dcp1a migrated as a single lower band as
compared to a non-treated control. This observation supports our
initial assumption that Dcp1a upper band is a phosphorylated form
of the protein. We used another cell model for neuronal differenti-
ation, P19 embryonic carcinoma (EC) cells, and monitored Dcp1a
expression during neuronal differentiation. These cells are cultured
in suspension while treated with retinoic acid (RA) for 4 days. After
4 days the cells are plated, and by day 8 (post RA treatment) a clear
neuronal phenotype is visible. We analyzed Dcp1a expression in
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neuronal differentiation. Dcp1a migrated as two distinct bands
after 2 days of RA treatment (D2), similarly to its expression in
non-differentiated P19 cells (ND). After 4 days of RA treatment
(D4) the lower band disappeared and Dcp1a migrated as one upper
band (compared to ND and D2 samples) (Fig. 1B). These results
show a correlation between neuronal development stage and the
phosphorylation level of Dcp1a protein.Fig. 2. Arsenate induces P-bodies disassembly and Dcp1a phosphorylation in 293 HEK ce
and arsenate treated 293 HEK cells, scale bar = 10 lm. (B) Protein samples from 293 HEK
examined for the presence of Dcp1a protein. Phosphatase treatment of protein samples
Fig. 3. Dcp1a mutations expression analysis using SDS–PAGE. (A) Schematic representa
analysis of Dcp1a mutations as compared to the WT YFP-Dcp1a vector. Arrows mark th3.2. Arsenate treatment induces P-bodies disassembly and Dcp1a
phosphorylation
We followed our results revealing Dcp1a phosphorylation and
monitored Dcp1a expression in response to sodium arsenate. So-
dium arsenate is a toxic agent which inhibits glycolysis and in-
duces a cellular stress response [15,16]. This agent is commonly
used in order to study the effect of cellular stress and the assemblylls. (A) Fluorescence microscopy analysis using Dcp1a and TIAR antibodies of control
cells of control and arsenate treated cells were separated in 8% SDS–PAGE gel and
from arsenate treated cells were similarly analyzed.
tion of phosphorylation sites as predicted by the PHOSIDA database. (B) SDS–PAGE
e double bands.
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nate (1 mM 30 min) and visualized the expression of Dcp1a and
TIAR (TIA-1 related protein) as a stress granules marker. In control
cells Dcp1a is localized in few large P-bodies in the cytoplasm and
TIAR is found mainly in the cytoplasm and in the nucleus of the
cells. Upon arsenate treatment, P-bodies are disrupted and Dcp1a
localizes in smaller granules in the cytoplasm. TIAR protein, on
the other hand, is found as part of large cytoplasmic stress granules
(Fig. 2A). Please note that there is no colocalization between Dcp1a
containing granules and stress granules. In addition, arsenate treat-
ment induced hyperphosphorylation of Dcp1a protein in 293 HEK
cells (Fig. 2B). This observation was veriﬁed by incubating protein
samples of arsenate treated cells with phosphatase prior to SDS–
PAGE analysis. Arsenate may induce additional post-translational
modiﬁcations of Dcp1a, since an upper band of Dcp1a protein is
still visible after phosphatase treatment.
3.3. Identiﬁcation of phosphorylated residues of Dcp1a
In order to identify Dcp1a amino acid residues that are putative
phosphorylation sites, we combined both bioinformatics tools and
site-directed mutagenesis. We searched the PHOSIDA-phosphory-
lation site database at http://www.phosida.com/ [17] for phos-
phorylation sites of the hDcp1a (Swiss-Prot entry: Q9NPI6). The
database search predicted six possible phosphorylation sites on
either serine or threonine amino acid residues, as described in
Fig. 3A. We performed site-directed mutagenesis on hDcp1a se-
quence (cloned in a YFP vector), and mutated each residue to an
alanine amino acid. We monitored the expression of YFP-Dcp1a
and the mutants and found that mutations of S142, S144 and
S353 had no effect on the protein migration as compared to YFP-
Dcp1a (data not shown). When we followed the expression of
S315, S319 and T321 mutants, we noticed that mutations of S319
and T321 amino acids migrated as double bands, whereas S315
mutation appeared as a single lower band (Fig. 3B). Interestingly,
a triple mutation on S315/S319/T321 amino acids migrated as anFig. 4. Arsenate effect on Dcp1a mutations. Two-hundred and ninety three HEK
cells were transfected with either control YFP-Dcp1a vector or mutated Dcp1a
protein followed by sodium arsenate treatment. (A) SDS–PAGE analysis of Dcp1a
mutations following arsenate treatment. (B) SDS–PAGE analysis of the triple
mutated Dcp1a protein as compare to YFP-Dcp1a control.even lower single band compared to the migration of the S315
mutant.
3.4. Arsenate effect on Dcp1a mutations
Following our previous results demonstrating that sodium arse-
nate induces hyperphosphorylation of Dcp1a, we analyzed its ef-
fect on the phosphorylation of Dcp1a mutants. We expressed
YFP-Dcp1a plasmids harboring each of the mutations in 293 HEK
cells prior to arsenate treatment of the cells. We monitored the
mutations expression following arsenate treatment. Sodium arse-
nate induced a shift in the migration of YFP-Dcp1a and the single
mutations towards an upper band (Fig. 4A). The migration patterns
of the mutant proteins and YFP-Dcp1a WT plasmid following arse-
nate treatment are similar. However, sodium arsenate treatment
induced only a minor upward shift in the band of the triple mu-
tated protein compared to its robust effect on the WT YFP-Dcp1a
protein (Fig. 4B).4. Discussion
Dcp1a is a key component in the processes of mRNA decapping
and degradation. Although these processes were thoroughly stud-
ied, the functional regulation of Dcp1a protein is poorly under-
stood. In this study we examined the expression of Dcp1a
protein under various physiological conditions. We found that dur-
ing brain development, Dcp1a migrated as two distinct bands
(Fig. 1A). The upper band was a phosphorylated form of Dcp1a,
as was determined by phosphatase treatment. This observation
correlates well with previous data suggesting that Dcp1p, the yeast
homologue of Dcp1a, is a phosphoprotein [7]. In order to further
investigate Dcp1a in neurons, we monitored its expression during
P19 EC neuronal differentiation. In this model system, Dcp1a
expression revealed a similar pattern of two distinct bands in the
ﬁrst 48 h post RA application. However, after 48 h the expression
of the lower band was signiﬁcantly reduced and only the upper
band was observed (Fig. 1B). Phosphorylation of Dcp1a suggests
that Dcp1a is part of a signaling pathway, which is activated during
neuronal and brain development.
Following our previous results, we had speculated that Dcp1a
could undergo phosphorylation upon other stimulations. We mon-
itored the effect of sodium arsenate treatment of 293 HEK cells on
Dcp1a expression. Sodium arsenate is a known potent toxin that
inhibits glycolysis and promotes the formation of stress granules
[12,15,16]. Using ﬂuorescence microscopy we found that applica-
tion of arsenate induced both disassembly of Dcp1a granules and
formation of stress granules (Fig. 2A). In addition, Dcp1a in protein
samples taken from arsenate treated cells migrated on SDS–PAGE
as a single upper band (as compared to control samples). The
expression of Dcp1a as a single upper band is partially due to phos-
phorylation modiﬁcations of the protein as veriﬁed by phosphatase
treatment of the sample (Fig. 2B). We show here that Dcp1a phos-
phorylation can be induced by activation of cellular stress mecha-
nisms. In addition, there might be a correlation between arsenate
effects on P-body structure and Dcp1a hyperphosphorylation.
In order to identify phosphorylated amino acid residues of
Dcp1a, we utilized bioinformatics tools. By using the PHOSIDA
database combined with site-directed mutagenesis, we were able
to identify 3 amino acids in Dcp1a sequence as possible phosphor-
ylation sites (Fig. 3A). When all three were mutated (S315, S319,
T321), the mutated protein migrated as a single lower band. When
single mutations were introduced and analyzed, only the S315 mu-
tant migrated as a single band, higher than the triple mutant pro-
tein (Fig. 3B). These results suggest that all three amino acids are
necessary for Dcp1a phosphorylation in 293 HEK cells.
J. Blumenthal et al. / FEBS Letters 583 (2009) 197–201 201We further analyzed the effect of arsenate treatment on each of
the mutations. We expressed each of the mutations in 293 HEK
cells prior to arsenate treatment followed by SDS–PAGE analysis.
Our results demonstrate that each of the mutations migrated as a
single upper band in response to arsenate treatment (Fig. 4A).
Interestingly, arsenate treatment induced only a minor shift in
the triple mutant protein, as compared to the shift of YFP-Dcp1a
protein (Fig. 4B). From these observations we learn that arsenate
can either promote Dcp1a phosphorylation on other amino acid
residues than the ones we had mutated, or other post-translational
modiﬁcations are involved.
In this study we examined the expression of Dcp1a protein dur-
ing neuronal development and under stress conditions. Dcp1a is a
key component in the mRNA decapping and degradation machin-
ery and was previously shown to take part in the SMAD4-TGF-b
pathway. We show that Dcp1a is subjected to phosphorylation
events along neuronal development and in response to arsenate-
induced cellular stress. Using bioinformatics, we identiﬁed three
amino acids in Dcp1a sequence, that are phosphorylated under
these conditions. Taken together, our results suggest that physio-
logical changes may inﬂuence RNA regulation via post-transla-
tional modiﬁcations of Dcp1a.
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